Cargando…

Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled study

BACKGROUND: Indacaterol is a long-acting beta-2 agonist for once-daily treatment of COPD. We evaluated the effects of indacaterol 150 μg on lung hyperinflation compared with placebo and open-label tiotropium 18 μg. We measured physical activity during treatment with indacaterol 150 μg and matched pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watz, Henrik, Krippner, Felix, Kirsten, Anne, Magnussen, Helgo, Vogelmeier, Claus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197315/ https://www.ncbi.nlm.nih.gov/pubmed/25280934 http://dx.doi.org/10.1186/1471-2466-14-158

Ejemplares similares

Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)
por: Watz, Henrik, et al.
Publicado: (2016)

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial
por: Beeh, Kai M, et al.
Publicado: (2014)

Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD
por: Alter, Peter, et al.
Publicado: (2019)

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
por: Vogelmeier, Claus, et al.
Publicado: (2010)

Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial
por: Santus, Pierachille, et al.
Publicado: (2015)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
por: Herth, Felix, et al.
Publicado: (2020)

Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET
por: Alter, Peter, et al.
Publicado: (2020)

Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline
por: Ferguson, Gary T, et al.
Publicado: (2020)

Brain Activation during Perception and Anticipation of Dyspnea in Chronic Obstructive Pulmonary Disease
por: Esser, Roland W., et al.
Publicado: (2017)

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial
por: Watz, Henrik, et al.
Publicado: (2018)

Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study
por: Fujimoto, Keisaku, et al.
Publicado: (2017)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
por: Balint, Beatrix, et al.
Publicado: (2010)

Influence of body mass on predicted values of static hyperinflation in COPD
por: Alter, Peter, et al.
Publicado: (2018)

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
por: Vogelmeier, Claus F., et al.
Publicado: (2017)

Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease
por: Rodriguez-Roisin, Roberto, et al.
Publicado: (2016)

Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial
por: Divo, Miguel J., et al.
Publicado: (2020)

Pathogenesis of hyperinflation in chronic obstructive pulmonary disease
por: Gagnon, Philippe, et al.
Publicado: (2014)

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
por: Ribeiro, Marcos, et al.
Publicado: (2012)

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
por: Halpin, David M.G., et al.
Publicado: (2021)

Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials
por: Han, Jiangna, et al.
Publicado: (2013)

Cardiovascular effects of exercise induced dynamic hyperinflation in COPD patients—Dynamically hyperinflated and non-hyperinflated subgroups
por: Lukacsovits, Jozsef, et al.
Publicado: (2023)

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
por: Watz, Henrik, et al.
Publicado: (2017)

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
por: Greulich, Timm, et al.
Publicado: (2018)

Spontaneous Hyperinflation of an Intragastric Balloon Causing Gastric Outlet Obstruction
por: Bomman, Shivanand, et al.
Publicado: (2021)

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function
por: Waschki, Benjamin, et al.
Publicado: (2017)

Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis
por: Bahmer, Thomas, et al.
Publicado: (2017)

Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis
por: Chung, Vincent C. H., et al.
Publicado: (2013)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
por: Vogelmeier, Claus, et al.
Publicado: (2016)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023)

Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort
por: Singh, Mukesh P
Publicado: (2013)

Manual hyperinflation in children
por: Lorena, Daiane Menezes, et al.
Publicado: (2021)

Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial
por: Beier, Jutta, et al.
Publicado: (2021)

Ghrelin Treatment of Cachectic Patients with Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Miki, Keisuke, et al.
Publicado: (2012)

Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study
por: Feldman, Gregory, et al.
Publicado: (2010)

Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol
por: Feldman, Gregory J
Publicado: (2013)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease
por: Hataji, Osamu, et al.
Publicado: (2013)

Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea
por: Yum, Ho-Kee, et al.
Publicado: (2017)

Targeting dynamic hyperinflation in moderate-to-severe asthma: a randomised controlled trial
por: van der Meer, Akke-Nynke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ku0f2derfq55upgtfig4gdv69c